Roche has entered an agreement to acquire Santaris Pharma, a privately held Denmark-based biopharma company for $250 million in cash up front and additional payments of as much as $200 million based on certain milestones. Santaris’ Locked Nucleic Acid (LNA) platform is focused on the discovery and development of RNA-targeting therapeutics, a new class of medicines with the potential to address hard to treat diseases.   The acquisition, subject to customary closing conditions, is expected to clos...